BSD Medical Corporation Listed on Russell Microcap Index
Posted on: Thursday, 6 July 2006, 09:03 CDT
SALT LAKE CITY, July 6 /PRNewswire-FirstCall/ -- BSD Medical Corp. today announced that BSD Medical has been listed on the new Russell Microcap(TM) Index. BSD was previously named on the preliminary index, and now has joined the official index as published by Russell.
Russell indexes rank as the most used set of U.S. equity performance benchmarks. The indexes are widely utilized by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Investment managers who oversee these funds purchase shares of member stocks according to that company's weighting in the particular index.
BSD Medical produces cancer treatment systems, and has been a pioneer in medical technologies that deliver precision-guided RF and microwave heat used in the treatment of cancer and other diseases. BSD developed and commercialized technology that has become widely used in the treatment of health problems caused by benign enlarged prostate, providing a major contribution to men's health. The company has since sold its interests in that venture and focused its full resources on providing advanced solutions for the treatment of cancer, the leading cause of death in the United States. BSD Medical's systems are used to kill cancer directly and increase the effectiveness of radiation therapy. For further information about BSD Medical and its technologies visit the BSD website at http://www.bsdmedical.com/.
Statements contained in this press release that are not historical facts are forward-looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements and projections or expectations of future events, including the future broad commercial use of the company's cancer treatment systems in therapy, are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
BSD Medical Corp.
CONTACT: Hyrum A. Mead of BSD Medical Corp., +1-801-972-5555, or fax,+1-801-972-5930, investor@bsdmc.com
Web site: http://www.bsdmedical.com/
Source: PRNewswire-FirstCall
Related Articles
- BSD Medical's Cancer Treatment Systems Get an 80% Reimbursement Boost From Medicare
- Major Study of BSD Medical's Cancer Therapy in Combination With Chemotherapy Highlighted in ASCO News and in Summary Session
- Results of 340 Patient Phase III Study Using BSD Medical's Cancer Therapy Systems to Be Announced at ASCO Annual Meeting
- BSD Medical Presents Cutting-Edge Cancer Treatment Systems at New York Oncology Congress
- BSD Medical Launches Interactive Cancer Website for Physicians
- BSD Medical's Award-Winning Website Brings Hope to Thousands With Cancer
- New Coding Change Increases Reimbursement Applicable to BSD Medical's Cancer Treatment Systems in Germany
- BSD Medical Launches Campaign to Take Its Cancer Therapy to Patients
- BSD Medical's Cancer Systems Showcased in 3 Prestigious Hospitals and International Conference
- Report in CANCER Shows 90 Percent Complete Remission With Advanced BSD Medical System
 |
 |
User Comments (0)
RSS Feeds